

July 5, 2024
Web Announcement 3387

Silver State Scripts Board (SSSB) Made Changes to Preferred Drug List (PDL) Effective July 5, 2024

The Silver State Scripts Board (SSSB) met on June 20, 2024 and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective July 5, 2024.

The complete PDL is posted on the [“Preferred Drug List”](#) webpage.

Drug Class/Program	Changes
Vasodilators - Oral	<ul style="list-style-type: none"> • Opsyndi® added as non-preferred • Revatio® tablet and suspension moved from preferred to non-preferred • Sildenafil tablet and suspension moved from non-preferred to preferred • Tracleer® tablet for suspension added as non-preferred
Topical Anti-infectives, vaginal	<ul style="list-style-type: none"> • New drug class added to PDL • Cleocin® cream, Cleocin® ovules, metronidazole (generic for Vandazole®), and Nuversa® added as preferred • Generic clindamycin, Clindesse®, Vandazole®, and Xaciato® added as non-preferred
Skeletal Muscle Relaxants	<ul style="list-style-type: none"> • Carisoprodol added as a new agent to PDL, with 350 mg dose as preferred and 250 mg dose non-preferred • Chlorzoxazone 500 mg strength defined as preferred product, all other strengths (250 mg, 375 mg, and 750 mg) moved to non-preferred
Biguanides	<ul style="list-style-type: none"> • Riomet® ER suspension added as preferred • Metformin 625 mg strength added as non-preferred
Fibric Acid Derivatives	<ul style="list-style-type: none"> • Generic for Antara®, Lofibra®, and Tricor® (fenofibrate) kept as preferred • Generic for Fenoglide® and Lipofen® (fenofibrate) switched to non-preferred • Generic for Trilipix® (fenofibric acid) kept as preferred • Generic for Fibracor® (fenofibric acid) switched to non-preferred • Lipofen® branded product moved from non-preferred to preferred
Proton Pump Inhibitors (PPIs)	<ul style="list-style-type: none"> • Dexilant® moved from preferred to non-preferred • Dexlansoprazole added to non-preferred list • Nexium® powder for suspension moved from preferred to non-preferred • Prilosec® OTC removed from PDL due to manufacturer no longer participating in Medicaid Drug Rebate Program
Functional Gastrointestinal Disorder Drugs	<ul style="list-style-type: none"> • Amitiza® moved from preferred to non-preferred • Lubiprostone moved from non-preferred to preferred
ADHD Agents	<ul style="list-style-type: none"> • Amphetamine salts combo ER (generic for Adderall XR®) moved from non-preferred to preferred • Methylphenidate ER (generic for Concerta®) added to preferred list
Phosphate Binding Agents	<ul style="list-style-type: none"> • Renvela® moved from preferred to non-preferred • Sevelamer carbonate moved from non-preferred to preferred